Shailender Bhatia1, Barry E Storer2, Jayasri G Iyer2, Ata Moshiri2, Upendra Parvathaneni2, David Byrd2, Arthur J Sober2, Vernon K Sondak2, Jeffrey E Gershenwald2, Paul Nghiem1. 1. University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA (SB, BES, JGI, AM, UP, DB, PN); Massachusetts General Hospital, Boston, MA (AJS); H. Lee Moffitt Cancer Center, Tampa, FL (VKS); The University of Texas MD Anderson Cancer Center, Houston, TX (JEG) sbhatia@uw.edu pnghiem@uw.edu. 2. University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA (SB, BES, JGI, AM, UP, DB, PN); Massachusetts General Hospital, Boston, MA (AJS); H. Lee Moffitt Cancer Center, Tampa, FL (VKS); The University of Texas MD Anderson Cancer Center, Houston, TX (JEG).
Abstract
BACKGROUND: Merkel cell carcinoma (MCC) has a high risk of recurrence after initial surgical therapy. Adjuvant radiation therapy (RT) and chemotherapy may be used to reduce the risk of locoregional and systemic recurrence, respectively, but there are conflicting data regarding their impact on survival. We performed a retrospective analysis of MCC cases from the National Cancer Data Base (NCDB) to assess whether adjuvant therapy was associated with differences in survival. METHODS: Six thousand nine hundred and eight MCC patients with staging, treatment, and survival data were included. Multivariable analyses were conducted for overall survival (OS) with various treatment modalities while adjusting for prognostic variables including age, sex, comorbidities (Charlson/Deyo score), margin status, primary tumor site and size, and lymph node status. All statistical tests were two-sided. RESULTS: For localized MCC (stage I: n = 3369, stage II: n = 1474 ), surgery plus adjuvant RT was associated with statistically significantly better OS than with surgery alone in multivariable analyses (stage I: hazard ratio [HR] = 0.71, 95% confidence interval [CI] = 0.64 to 0.80, P < .001; stage II: HR = 0.77, 95% CI = 0.66 to 0.89, P < .001). In patients with regional nodal metastases (stage III: n = 2065 ), neither adjuvant RT nor chemotherapy was associated with statistically significantly improved or worsened OS. CONCLUSIONS: In this study of the largest MCC cohort reported to date, adjuvant RT was associated with improved OS in stages I-II MCC. Neither adjuvant RT nor chemotherapy was associated with improved OS in stage III MCC. These results, with the limitations of retrospective analyses, are consistent with earlier studies suggesting benefit with adjuvant RT but do not support the routine use of adjuvant chemotherapy in MCC.
BACKGROUND:Merkel cell carcinoma (MCC) has a high risk of recurrence after initial surgical therapy. Adjuvant radiation therapy (RT) and chemotherapy may be used to reduce the risk of locoregional and systemic recurrence, respectively, but there are conflicting data regarding their impact on survival. We performed a retrospective analysis of MCC cases from the National Cancer Data Base (NCDB) to assess whether adjuvant therapy was associated with differences in survival. METHODS: Six thousand nine hundred and eight MCC patients with staging, treatment, and survival data were included. Multivariable analyses were conducted for overall survival (OS) with various treatment modalities while adjusting for prognostic variables including age, sex, comorbidities (Charlson/Deyo score), margin status, primary tumor site and size, and lymph node status. All statistical tests were two-sided. RESULTS: For localized MCC (stage I: n = 3369, stage II: n = 1474 ), surgery plus adjuvant RT was associated with statistically significantly better OS than with surgery alone in multivariable analyses (stage I: hazard ratio [HR] = 0.71, 95% confidence interval [CI] = 0.64 to 0.80, P < .001; stage II: HR = 0.77, 95% CI = 0.66 to 0.89, P < .001). In patients with regional nodal metastases (stage III: n = 2065 ), neither adjuvant RT nor chemotherapy was associated with statistically significantly improved or worsened OS. CONCLUSIONS: In this study of the largest MCC cohort reported to date, adjuvant RT was associated with improved OS in stages I-II MCC. Neither adjuvant RT nor chemotherapy was associated with improved OS in stage III MCC. These results, with the limitations of retrospective analyses, are consistent with earlier studies suggesting benefit with adjuvant RT but do not support the routine use of adjuvant chemotherapy in MCC.
Authors: Ryan C Fields; Klaus J Busam; Joanne F Chou; Katherine S Panageas; Melissa P Pulitzer; Peter J Allen; Dennis H Kraus; Mary S Brady; Daniel G Coit Journal: Cancer Date: 2011-11-09 Impact factor: 6.860
Authors: Bianca D Lemos; Barry E Storer; Jayasri G Iyer; Jerri Linn Phillips; Christopher K Bichakjian; L Christine Fang; Timothy M Johnson; Nanette J Liegeois-Kwon; Clark C Otley; Kelly G Paulson; Merrick I Ross; Siegrid S Yu; Nathalie C Zeitouni; David R Byrd; Vernon K Sondak; Jeffrey E Gershenwald; Arthur J Sober; Paul Nghiem Journal: J Am Acad Dermatol Date: 2010-06-19 Impact factor: 11.527
Authors: James Jabbour; Robert Cumming; Richard A Scolyer; George Hruby; John F Thompson; Stephen Lee Journal: Ann Surg Oncol Date: 2007-03-14 Impact factor: 5.344
Authors: Kelly G Paulson; Jayasri G Iyer; Andrew R Tegeder; Renee Thibodeau; Janell Schelter; Shinichi Koba; David Schrama; William T Simonson; Bianca D Lemos; David R Byrd; David M Koelle; Denise A Galloway; J Helen Leonard; Margaret M Madeleine; Zsolt B Argenyi; Mary L Disis; Juergen C Becker; Michele A Cleary; Paul Nghiem Journal: J Clin Oncol Date: 2011-03-21 Impact factor: 44.544
Authors: Michelle Heath; Natalia Jaimes; Bianca Lemos; Arash Mostaghimi; Linda C Wang; Pablo F Peñas; Paul Nghiem Journal: J Am Acad Dermatol Date: 2008-03 Impact factor: 11.527
Authors: M Suntharalingam; M S Rudoltz; W M Mendenhall; J T Parsons; S P Stringer; R R Million Journal: Head Neck Date: 1995 Mar-Apr Impact factor: 3.147
Authors: Kelly G Paulson; Jayasri G Iyer; Astrid Blom; E Margaret Warton; Monica Sokil; Lola Yelistratova; Louise Schuman; Kotaro Nagase; Shailender Bhatia; Maryam M Asgari; Paul Nghiem Journal: J Invest Dermatol Date: 2012-11-29 Impact factor: 8.551
Authors: Rocio Garcia-Carbonero; Ivan Marquez-Rodas; Luis de la Cruz-Merino; Javier Martinez-Trufero; Miguel Angel Cabrera; Jose Maria Piulats; Jaume Capdevila; Enrique Grande; Salvador Martin-Algarra; Alfonso Berrocal Journal: Oncologist Date: 2019-04-08
Authors: Jürgen C Becker; Andreas Stang; James A DeCaprio; Lorenzo Cerroni; Celeste Lebbé; Michael Veness; Paul Nghiem Journal: Nat Rev Dis Primers Date: 2017-10-26 Impact factor: 52.329